Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 44370 BS

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 8

Registration Number: NCT02215772

The Use of Angiotensin Receptor Blockers and the Risk of Cancer

Completed

Conditions: Neoplasm

Interventions: Drug: ARB
Drug: ACEI
Drug: Beta-blockers
Drug: Diuretics
Drug: Telmisartan

First Posted Date: 2014-08-13

Last Posted Date: 2014-08-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1165781

Registration Number: NCT02215733

Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BI 2536

First Posted Date: 2014-08-08

Last Posted Date: 2024-12-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 70

Registration Number: NCT02211859

Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BI 2536
Drug: Pemetrexed

First Posted Date: 2014-08-08

Last Posted Date: 2014-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 41

Registration Number: NCT02211833

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Phase 1

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: BI 14332 CL

First Posted Date: 2014-08-08

Last Posted Date: 2014-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 38

Registration Number: NCT02212925

Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and Their Combination in Constipation and Bloatedness

Phase 3

Completed

Conditions: Constipation

Interventions: Drug: Bisacodyl
Drug: Simeticone

First Posted Date: 2014-08-08

Last Posted Date: 2014-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02211976

Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bisacodyl
Drug: Sodium picosulfate

First Posted Date: 2014-08-08

Last Posted Date: 2014-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02211911

Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux

Phase 3

Completed

Conditions: Venous Insufficiency

Interventions: Drug: BNS003

First Posted Date: 2014-08-08

Last Posted Date: 2014-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 180

Registration Number: NCT02211898

Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 44847
Other: Japanese diet
Drug: Acarbose

First Posted Date: 2014-08-08

Last Posted Date: 2014-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT02211950

Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 14332 CL
Other: high fat breakfast

First Posted Date: 2014-08-08

Last Posted Date: 2014-08-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02212938

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy